Autoantibodies to CD4 in HIV Type 1-Exposed Seronegative Individuals

Samuele E. Burastero(Vita-Salute San Raffaele University), A. Beretta(San Raffaele University of Rome), Davide Gaffi(Vita-Salute San Raffaele University), Antonio G. Siccardi(San Raffaele University of Rome), Anna Maria Gasparri(Vita-Salute San Raffaele University), Piera Robbioni(Vita-Salute San Raffaele University), Barbara Borgonovo(Vita-Salute San Raffaele University), Giuseppe Tambussi(San Raffaele University of Rome), CLAUDIA ABECASIS, C. De Santis(University of Milan), Lucia Lopalco(Vita-Salute San Raffaele University), F Celada(Vita-Salute San Raffaele University), Adriano Lazzarin(Vita-Salute San Raffaele University)
AIDS Research and Human Retroviruses
March 1, 1996
10.1089/aid.1996.12.273
Cited by 34

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
|Nature Medicine|1997|635
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Control of HIV despite the Discontinuation of Antiretroviral Therapy
|New England Journal of Medicine|1999|328